Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA. Claim Rejections - 35 USC § 103 In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. The factual inquiries for establishing a background for determining obviousness under 35 U.S.C. 103 are summarized as follows: 1. Determining the scope and contents of the prior art. 2. Ascertaining the differences between the prior art and the claims at issue. 3. Resolving the level of ordinary skill in the pertinent art. 4. Considering objective evidence present in the application indicating obviousness or nonobviousness . This application currently names joint inventors. In considering patentability of the claims the examiner presumes that the subject matter of the various claims was commonly owned as of the effective filing date of the claimed invention(s) absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and effective filing dates of each claim that was not commonly owned as of the effective filing date of the later invention in order for the examiner to consider the applicability of 35 U.S.C. 102(b)(2)(C) for any potential 35 U.S.C. 102(a)(2) prior art against the later invention. Claim s 1 -5 are rejected under 35 U.S.C. sec. 103 as being unpatentable as obvious in view of United States Patent Application Pub. No..: US2015/0202337A1 to DIPASQUA filed in 2014 and in view of International Patent Pub. No.: WO 1994/027633 A1 to Eckert et al. DIPASQUA discloses “... 1. A bandage comprising: an electrospun sheet comprising: (see abstract) a polyacrylonitrile nanofiber embedded with a carrier nanoparticle or a carrier particle comprising: (see paragraph 143 where there is a nanofibrous mat that includes an electro spun polymer material and including radiative and neutron activation materials in the covered area to damage dna in cancer cells) See also p ara 0005);[0046];(0051);[0067};[0068];[COSO};[0135];[0161] ) an activatable nuclide selected from the group consisting of yttrium-89, lanthanum-139, praseodymium-141, samarium-152, dysprosium-164, holmium- 1 65, rhenium-185, rhenium-187, and any combination thereof; and (see abstract where dysprosium 164 is used) ”. The primary reference is silent but Eckert teaches “... a laminate enclosure, enclosing the electrospun sheet; and wherein the bandage ” (see claims 1-10). DIPASQUA discloses “... has a distribution of the carrier nanoparticle or the carrier particle to emit a relatively uniform radiation across the surface area of the bandage after neutron-activation ” . (see claims 1-10 and paragraph 26-52 and 135)”. It would have been obvious for one of ordinary skill in the art before the effective filing date of the present disclosure to combine the disclosure of DIPASQUA with the teachings of ECKERT et al. to provide an electro spun bandage of FIG. 22 with nanoparticles that are radioactive to treat a disorder such as cancer and provide this in a bandage that includes two membranes for treating wounds using a fresh cellular product configuration with a permeable bottom membrane through which cellular product can diffuse and a separator between the two membranes for healing. See abstract. DIPASQUA discloses “... 2. The bandage of claim 1, wherein the carrier nanoparticle or the carrier particle further comprises carbon-based materials. (see paragraph 119) DIPASQUA discloses “... 3. The bandage of claim 1, wherein the carrier nanoparticle or the carrier particle further comprises lipid-based materials. 4, The bandage of claim 1, wherein the carrier nanoparticle or the carrier particle further comprises silica-based materials. ( see paragraph 135) DIPASQUA discloses “... 5. The bandage of claim 1, wherein the carrier nanoparticle or the carrier particle comprises a polymeric-based materials. ( see paragraph 23 and claims 18 ) ”. Claim s 6 -8 are rejected under 35 U.S.C. sec. 103 as being unpatentable as obvious in view of United States Patent Application Pub. No..: US2015/0202337A1 to DIPASQUA filed in 2014 and in view of International Patent Pub. No.: WO 1994/027633 A1 to Eckert et al. and in view of NPL, Junghyum et al., In-Situ formation of Holmium Oxide in Pores of Mesoporous Carbon Nanoparticles as Substrates for Neutron Activatable Radiotherapeutics, HHS Public Access, Carbon NY 2017. DIPASQUA is silent but Junghyum teaches “... 6. The bandage of claim 1, wherein the carrier nanoparticle or the carrier particle comprises a graphene-based material ” . (see page 2). It would have been obvious for one of ordinary skill in the art before the effective filing date of the present disclosure to combine the disclosure of DIPASQUA with the teachings of ECKERT et al. to provide an electro spun bandage of FIG. 22 with nanoparticles that are radioactive to treat a disorder such as cancer and provide this in a bandage that includes two membranes for treating wounds using a fresh cellular product configuration with a permeable bottom membrane through which cellular product can diffuse and a separator between the two membranes for healing. See abstract. It would have been obvious for one of ordinary skill in the art before the effective filing date of the present disclosure to combine the disclosure of DIPASQUA with the teachings of JUNGHYUN et al. since it teaches that a neutron activatable radiotherapeutic device can include graphene for providing some shielding when desired. Cool graphene composites block EM radiation and acts as an advanced shielding material against various types of radiation by absorbing or reflecting electromagnetic (EM) waves and ionizing radiation, including X-rays and gamma rays and provide a focused application. See abstract. DIPASQUA is silent but Junghyum teaches “.. 7. The bandage of claim 2, wherein the carbon-based material consists of mesoporous carbon. (see page 1-2) It would have been obvious for one of ordinary skill in the art before the effective filing date of the present disclosure to combine the disclosure of DIPASQUA with the teachings of JUNGHYUN et al. since it teaches that a neutron activatable radiotherapeutic device can include graphene for providing some shielding when desired. Cool graphene composites block EM radiation acts as an advanced shielding material against various types of radiation by absorbing or reflecting electromagnetic (EM) waves and ionizing radiation, including X-rays and gamma rays and provide a focused application. See abstract. DIPASQUA is silent but Junghyum teaches “.. 8. The bandage of claim 4, wherein the silica-based material consists of mesoporous silica. (See section 1 where Di Pasqua et al. explored the use of mesoporous silica nanoparticles (MSNs) as a carrier for neutron-activatable isotopes for intraperitoneal administration ) It would have been obvious for one of ordinary skill in the art before the effective filing date of the present disclosure to combine the disclosure of DIPASQUA with the teachings of JUNGHYUN et al. since it teaches that a neutron activatable radiotherapeutic device can include graphene for providing some shielding when desired. Cool graphene composites block EM radiation – and acts as an advanced shielding material against various types of radiation by absorbing or reflecting electromagnetic (EM) waves and ionizing radiation, including X-rays and gamma rays and provide a focused application. See abstract. Claims 9-19 are rejected under 35 U.S.C. sec. 103 as being unpatentable as obvious in view of United States Patent Application Pub. No..: US2015/0202337A1 to DIPASQUA filed in 2014 and in view of International Patent Pub. No.: WO 1994/027633 A1 to Eckert et al. Eckert teaches “... 9. The bandage of claim 1, wherein the laminate is a polymer and fully encases the bandage. ” (see FIG. 1-2 and A variety of polymeric materials are used for the top membrane, such as, for example, polypropylene or polyethylene which are impermeable to fluids and do not elicit an immune response or inflammation. The top membrane alternatively may be comprised of materials of the type available under the trade name " Celgard 5550" from the Hoechst Celanese Company. Celgard 5550 is comprised of a uniform non-woven polypropylene fiber web and Celgard 2500, a polyethylene film. The Celgard 5550 has a pore size of 0.075 x 0.25 microns in diameter with 45% porosity and a moisture transmission rate of 460 g/m2/24 hours. Alternatively, " Metricel ® polypropylene," a hydrophobic membrane having a 0.1 micron pore size, available from Gelman Science, Inc., Ann Arbor, Michigan, is suitable. Also, suitable materials for the top membrane include those materials identified below as suitable for the bottom membrane 15. ) It would have been obvious for one of ordinary skill in the art before the effective filing date of the present disclosure to combine the disclosure of DIPASQUA with the teachings of ECKERT et al. to provide an electro spun bandage of FIG. 22 with nanoparticles that are radioactive to treat a disorder such as cancer and provide this in a bandage that includes two membranes for treating wounds using a fresh cellular product configuration with a permeable bottom membrane through which cellular product can diffuse and a separator between the two membranes for healing. See abstract. Eckert teaches “.. 10. The bandage of claim 9, wherein the polymer is selected from the group consisting of nylon, polyester, polypropylene, polyethylene, and combinations thereof ” . ( Polypure has a pore size of about 0.8 microns. Additional hydrophilic membranes include, for example, aerylate copolymer on non-woven nylon, available under the trade name " Versapor " from Gelman Sciences Company and cellulose acetate such as, for example, membranes available under the trade name "Acetate Plus" from Micron Separations, Inc. ) It would have been obvious for one of ordinary skill in the art before the effective filing date of the present disclosure to combine the disclosure of DIPASQUA with the teachings of ECKERT et al. to provide an electro spun bandage of FIG. 22 with nanoparticles that are radioactive to treat a disorder such as cancer and provide this in a bandage that includes two membranes for treating wounds using a fresh cellular product configuration with a permeable bottom membrane through which cellular product can diffuse and a separator between the two membranes for healing. See abstract. Eckert teaches “... 11. The bandage of claim 10, wherein the laminate covers all surfaces of the bandage and provides a sealed border around the sides of the bandage ” . ( Figure 1 the separator 30 is not affixed to the top membrane 14 nor to the bottom membrane 15. Instead, the edges 32, 34 of the top membrane 14 and the bottom membrane 15 extend beyond the separator 30 and the edges 32, 34 of top membrane 14 and bottom membrane 15 are directly sealed. Conventional techniques such as ultra sonic welding, heat sealing, impulse welding, adhesives, or the like, are used to provide a leakproof seal. Heat sealing is preferred. Where the top membrane 14 and bottom membranes 15 are both comprised of Cellguard , the heat sealing provides another advantage because when the two membranes are sealed they turn from opaque to clear. ) It would have been obvious for one of ordinary skill in the art before the effective filing date of the present disclosure to combine the disclosure of DIPASQUA with the teachings of ECKERT et al. to provide an electro spun bandage of FIG. 22 with nanoparticles that are radioactive to treat a disorder such as cancer and provide this in a bandage that includes two membranes for treating wounds using a fresh cellular product configuration with a permeable bottom membrane through which cellular product can diffuse and a separator between the two membranes for healing. See abstract. Eckert teaches “... 12. The bandage of claim 11, wherein the bandage has an adhesive applied to one surface ” . ( It is preferred that a layer of foam 21 be attached to the outer surface 22 of the top membrane 14 to provide rigidity to the bandage 10. The foam is of conventional materials, such as a closed cell polyurethane film-laminate, available from Semix Life Sciences Co., Frasier, Pennsylvania, preferably applied with an adhesive such as, for example, "Med 1118TT" from Avery Specialty Tape Co., Painsville , Ohio; or a tan spunlaced polyester film available under the trade name "5322P" from Avery Co. Preferably, the foam 21 is flesh colored for aesthetic purposes. ) It would have been obvious for one of ordinary skill in the art before the effective filing date of the present disclosure to combine the disclosure of DIPASQUA with the teachings of ECKERT et al. to provide an electro spun bandage of FIG. 22 with nanoparticles that are radioactive to treat a disorder such as cancer and provide this in a bandage that includes two membranes for treating wounds using a fresh cellular product configuration with a permeable bottom membrane through which cellular product can diffuse and a separator between the two membranes for healing. See abstract. Eckert teaches “... 13. The bandage of claim 10, wherein the laminate is nylon and has a tensile strength of at least 77220 kPa ” . ( Eckert teaches a glass matrix membrane nylon; 0.8μ and the Polypure has a pore size of about 0.8 microns. Additional hydrophilic membranes include, for example, aerylate copolymer on non-woven nylon, available under the trade name " Versapor " from Gelman Sciences Company and cellulose acetate such as, for example, membranes available under the trade name "Acetate Plus" from Micron Separations, Inc. The Versapor has a pore size of about 0.2 to 3μ and the Acetate Plus has a pore size of about 0.22μ to 0.8μ. Hydrophobic membranes must first be rendered hydrophilic to permit the cellular product to pass through the pores of the membrane. This is accomplished by the plasma treatment under a vacuum, to line the pores with hydrophilic groups, or by treating the membrane with a wound dressing such as Hypol . Other suitable membranes include glass matrix membranes, available from Gelman Sciences, Ann Arbor, Michigan, Millipore, Mass., and Anotec , United Kingdom. ) It would have been obvious for one of ordinary skill in the art before the effective filing date of the present disclosure to combine the disclosure of DIPASQUA with the teachings of ECKERT et al. to provide an electro spun bandage of FIG. 22 with nanoparticles that are radioactive to treat a disorder such as cancer and provide this in a bandage that includes two membranes for treating wounds using a fresh cellular product configuration with a permeable bottom membrane through which cellular product can diffuse and a separator between the two membranes for healing. See abstract. Eckert teaches “... 14. The bandage of claim 13, wherein the laminate has a thickness equal to or less than 0.5 mm ” . (see page 29). It would have been obvious for one of ordinary skill in the art before the effective filing date of the present disclosure to combine the disclosure of DIPASQUA with the teachings of ECKERT et al. to provide an electro spun bandage of FIG. 22 with nanoparticles that are radioactive to treat a disorder such as cancer and provide this in a bandage that includes two membranes for treating wounds using a fresh cellular product configuration with a permeable bottom membrane through which cellular product can diffuse and a separator between the two membranes for healing. See abstract. This is an obvious design choice that involves only routine skill. Eckert teaches “... 15. The bandage of claim 13, wherein the laminate has a thickness equal to or less than 25.4 um ” . ( The top membrane 14 is preferably made of a gas permeable, preferably hydrophilic, material which preferably bars the entry of organisms such as viruses and bacteria into the bandage. The top membrane should be permeable to gases such as oxygen and carbon dioxide, and have a thickness of from about 0.5 mils to about 20 mils, preferably about 6 mils. Preferably the top membrane 14 is comprised of a modified hydrophilic polysulfone , available under the trade name Z-Bind®, from Gelman Sciences, Inc. which has a pore size of about 0.2 - 0.4 micrometers. ) It would have been obvious for one of ordinary skill in the art before the effective filing date of the present disclosure to combine the disclosure of DIPASQUA with the teachings of ECKERT et al. to provide an electro spun bandage of FIG. 22 with nanoparticles that are radioactive to treat a disorder such as cancer and provide this in a bandage that includes two membranes for treating wounds using a fresh cellular product configuration with a permeable bottom membrane through which cellular product can diffuse and a separator between the two membranes for healing. See abstract. Eckert teaches “... 16. The bandage of claim 1, wherein the polyacrylonitrile nanofibers have a diameter from about 100 nm to about 350 nm ” . ( The potential growth hormone secreting cells were screened for secretion of growth hormone. The cells were grown until confluent in a 10 cm diameter dish (50 cm2) in normal growth media. The media was Dulbecco's Modified Eagle media in a 3 to 1 ratio with Ham's F12 and contained the supplements described above, and 80 ml fetal calf serum per liter. The cells were then shifted to serum-free growth media. After various periods of time (1-24 hours) , the medium was collected, concentrated and fractionated on a 12% polyacrylamide gel. The fractionated proteins were blotted to nitrocellulose and incubated with anti- bGH primary antibody followed by secondary incubation with 125 I-labelled protein A, from A ersham Inc. The bands were visualized by exposure on x-ray film (autoradiography) . ) It would have been obvious for one of ordinary skill in the art before the effective filing date of the present disclosure to combine the disclosure of DIPASQUA with the teachings of ECKERT et al. to provide an electro spun bandage of FIG. 22 with nanoparticles that are radioactive to treat a disorder such as cancer and provide this in a bandage that includes two membranes for treating wounds using a fresh cellular product configuration with a permeable bottom membrane through which cellular product can diffuse and a separator between the two membranes for healing. See abstract. Eckert teaches “... 17. The bandage of claim 16, wherein the polyacrylonitrile nanofibers have a diameter from about 150 nm to about 250 nm :” . (The potential growth hormone secreting cells were screened for secretion of growth hormone. The cells were grown until confluent in a 10 cm diameter dish (50 cm2) in normal growth media. The media was Dulbecco's Modified Eagle media in a 3 to 1 ratio with Ham's F12 and contained the supplements described above, and 80 ml fetal calf serum per liter. The cells were then shifted to serum-free growth media. After various periods of time (1-24 hours) , the medium was collected, concentrated and fractionated on a 12% polyacrylamide gel. The fractionated proteins were blotted to nitrocellulose and incubated with anti- bGH primary antibody followed by secondary incubation with 125 I-labelled protein A, from A ersham Inc. The bands were visualized by exposure on x-ray film (autoradiography) .) It would have been obvious for one of ordinary skill in the art before the effective filing date of the present disclosure to combine the disclosure of DIPASQUA with the teachings of ECKERT et al. to provide an electro spun bandage of FIG. 22 with nanoparticles that are radioactive to treat a disorder such as cancer and provide this in a bandage that includes two membranes for treating wounds using a fresh cellular product configuration with a permeable bottom membrane through which cellular product can diffuse and a separator between the two membranes for healing. See abstract. DIPASQUA discloses “... 18. The bandage of claim 1, wherein the nanoparticles or particles have diameters of about 15 nm to about 250 nm. (see paragraph 150-156). DIPASQUA discloses “.. 19. The bandage of claim 18, wherein the nanoparticles have diameters of about 15 nm to about 200 nm. (see paragraph 51-52) Claims 20- 32 are rejected under 35 U.S.C. sec. 103 as being unpatentable as obvious in view of United States Patent Application Pub. No..: US2015/0202337A1 to DIPASQUA filed in 2014 and in view of International Patent Pub. No.: WO 1994/027633 A1 to Eckert et al. DIPASQUA discloses “... 20. A bandage comprising: an electrospun sheet comprising: a polyacrylonitrile nanofiber embedded with an iron garnet nanoparticle or an iron garnet particle comprising: an activatable nuclide selected from the group consisting of yttrium-89, lanthanum-139, praseodymium-141, samarium-152, dysprosium-164, holmium-165, rhenium-185, rhenium-187, and combinations thereof; ... has a distribution of the iron garnet nanoparticle or the iron garnet particle to emit a relatively uniform radiation across the surface area of the bandage after neutron-activation. (see paragraph 143 where there is a nanofibrous mat that includes an electro spun polymer material and including radiative and neutron activation materials in the covered area to damage dna in cancer cells) See also paragraphs 0005);[0046];(0051);[0067};[0068];[COSO};[0135];[0161]) (see abstract where dysprosium 164 is used)”. Eckert teaches “... and a laminate enclosure, enclosing the electrospun sheet; and wherein the bandage ....”. (see claims 1-10). It would have been obvious for one of ordinary skill in the art before the effective filing date of the present disclosure to combine the disclosure of DIPASQUA with the teachings of ECKERT et al. to provide an electro spun bandage of FIG. 22 with nanoparticles that are radioactive to treat a disorder such as cancer and provide this in a bandage that includes two membranes for treating wounds using a fresh cellular product configuration with a permeable bottom membrane through which cellular product can diffuse and a separator between the two membranes for healing. See abstract. Eckert teaches “... 21. The bandage of claim 20, wherein the laminate enclosure is a polymer fully encasing the bandage. ” (see FIG. 1-2 and A variety of polymeric materials are used for the top membrane, such as, for example, polypropylene or polyethylene which are impermeable to fluids and do not elicit an immune response or inflammation. The top membrane alternatively may be comprised of materials of the type available under the trade name " Celgard 5550" from the Hoechst Celanese Company. Celgard 5550 is comprised of a uniform non-woven polypropylene fiber web and Celgard 2500, a polyethylene film. The Celgard 5550 has a pore size of 0.075 x 0.25 microns in diameter with 45% porosity and a moisture transmission rate of 460 g/m2/24 hours. Alternatively, " Metricel ® polypropylene," a hydrophobic membrane having a 0.1 micron pore size, available from Gelman Science, Inc., Ann Arbor, Michigan, is suitable. Also, suitable materials for the top membrane include those materials identified below as suitable for the bottom membrane 15.) It would have been obvious for one of ordinary skill in the art before the effective filing date of the present disclosure to combine the disclosure of DIPASQUA with the teachings of ECKERT et al. to provide an electro spun bandage of FIG. 22 with nanoparticles that are radioactive to treat a disorder such as cancer and provide this in a bandage that includes two membranes for treating wounds using a fresh cellular product configuration with a permeable bottom membrane through which cellular product can diffuse and a separator between the two membranes for healing. See abstract. Eckert teaches “... 22. The bandage of claim 21, wherein the laminate is selected from the group consisting of nylon, polyester, polypropylene, polyethylene, and combinations thereof ” ( Polypure has a pore size of about 0.8 microns. Additional hydrophilic membranes include, for example, aerylate copolymer on non-woven nylon, available under the trade name " Versapor " from Gelman Sciences Company and cellulose acetate such as, for example, membranes available under the trade name "Acetate Plus" from Micron Separations, Inc.) . It would have been obvious for one of ordinary skill in the art before the effective filing date of the present disclosure to combine the disclosure of DIPASQUA with the teachings of ECKERT et al. to provide an electro spun bandage of FIG. 22 with nanoparticles that are radioactive to treat a disorder such as cancer and provide this in a bandage that includes two membranes for treating wounds using a fresh cellular product configuration with a permeable bottom membrane through which cellular product can diffuse and a separator between the two membranes for healing. See abstract. Eckert teaches “... 23. The bandage of claim 22, wherein the laminate covers all surfaces of the bandage and provides a sealed border around the sides of the bandage ” . ( Figure 1 the separator 30 is not affixed to the top membrane 14 nor to the bottom membrane 15. Instead, the edges 32, 34 of the top membrane 14 and the bottom membrane 15 extend beyond the separator 30 and the edges 32, 34 of top membrane 14 and bottom membrane 15 are directly sealed. Conventional techniques such as ultra sonic welding, heat sealing, impulse welding, adhesives, or the like, are used to provide a leakproof seal. Heat sealing is preferred. Where the top membrane 14 and bottom membranes 15 are both comprised of Cellguard , the heat sealing provides another advantage because when the two membranes are sealed they turn from opaque to clear.) It would have been obvious for one of ordinary skill in the art before the effective filing date of the present disclosure to combine the disclosure of DIPASQUA with the teachings of ECKERT et al. to provide an electro spun bandage of FIG. 22 with nanoparticles that are radioactive to treat a disorder such as cancer and provide this in a bandage that includes two membranes for treating wounds using a fresh cellular product configuration with a permeable bottom membrane through which cellular product can diffuse and a separator between the two membranes for healing. See abstract. Eckert teaches “... 24. The bandage of claim 23, wherein the bandage has an adhesive applied to one surface ” . (It is preferred that a layer of foam 21 be attached to the outer surface 22 of the top membrane 14 to provide rigidity to the bandage 10. The foam is of conventional materials, such as a closed cell polyurethane film-laminate, available from Semix Life Sciences Co., Frasier, Pennsylvania, preferably applied with an adhesive such as, for example, "Med 1118TT" from Avery Specialty Tape Co., Painsville , Ohio; or a tan spunlaced polyester film available under the trade name "5322P" from Avery Co. Preferably, the foam 21 is flesh colored for aesthetic purposes.) It would have been obvious for one of ordinary skill in the art before the effective filing date of the present disclosure to combine the disclosure of DIPASQUA with the teachings of ECKERT et al. to provide an electro spun bandage of FIG. 22 with nanoparticles that are radioactive to treat a disorder such as cancer and provide this in a bandage that includes two membranes for treating wounds using a fresh cellular product configuration with a permeable bottom membrane through which cellular product can diffuse and a separator between the two membranes for healing. See abstract. Eckert teaches “.. 25. The bandage of claim 22, wherein the laminate is nylon and has a tensile strength of at least 77220 kPa ” . . ( Eckert teaches a glass matrix membrane nylon; 0.8μ and the Polypure has a pore size of about 0.8 microns. Additional hydrophilic membranes include, for example, aerylate copolymer on non-woven nylon, available under the trade name " Versapor " from Gelman Sciences Company and cellulose acetate such as, for example, membranes available under the trade name "Acetate Plus" from Micron Separations, Inc. The Versapor has a pore size of about 0.2 to 3μ and the Acetate Plus has a pore size of about 0.22μ to 0.8μ. Hydrophobic membranes must first be rendered hydrophilic to permit the cellular product to pass through the pores of the membrane. This is accomplished by the plasma treatment under a vacuum, to line the pores with hydrophilic groups, or by treating the membrane with a wound dressing such as Hypol . Other suitable membranes include glass matrix membranes, available from Gelman Sciences, Ann Arbor, Michigan, Millipore, Mass., and Anotec , United Kingdom.) It would have been obvious for one of ordinary skill in the art before the effective filing date of the present disclosure to combine the disclosure of DIPASQUA with the teachings of ECKERT et al. to provide an electro spun bandage of FIG. 22 with nanoparticles that are radioactive to treat a disorder such as cancer and provide this in a bandage that includes two membranes for treating wounds using a fresh cellular product configuration with a permeable bottom membrane through which cellular product can diffuse and a separator between the two membranes for healing. See abstract. Eckert teaches “... 26. The bandage of claim 22, wherein the laminate has a thickness equal to or less than 0.5 mm. ( see page 29). Eckert teaches “... 27. The bandage of claim 22, wherein the laminate has a thickness equal to or less than 25.4 um. (The top membrane 14 is preferably made of a gas permeable, preferably hydrophilic, material which preferably bars the entry of organisms such as viruses and bacteria into the bandage. The top membrane should be permeable to gases such as oxygen and carbon dioxide, and have a thickness of from about 0.5 mils to about 20 mils, preferably about 6 mils. Preferably the top membrane 14 is comprised of a modified hydrophilic polysulfone , available under the trade name Z-Bind®, from Gelman Sciences, Inc. which has a pore size of about 0.2 - 0.4 micrometers.) It would have been obvious for one of ordinary skill in the art before the effective filing date of the present disclosure to combine the disclosure of DIPASQUA with the teachings of ECKERT et al. to provide an electro spun bandage of FIG. 22 with nanoparticles that are radioactive to treat a disorder such as cancer and provide this in a bandage that includes two membranes for treating wounds using a fresh cellular product configuration with a permeable bottom membrane through which cellular product can diffuse and a separator between the two membranes for healing. See abstract. Eckert teaches “... 28. The bandage of claim 20, wherein the polyacrylonitrile nanofiber or polyacrylonitrile fiber has a diameter from about 100 nm to about 350 nm ” . ( The potential growth hormone secreting cells were screened for secretion of growth hormone. The cells were grown until confluent in a 10 cm diameter dish (50 cm2) in normal growth media. The media was Dulbecco's Modified Eagle media in a 3 to 1 ratio with Ham's F12 and contained the supplements described above, and 80 ml fetal calf serum per liter. The cells were then shifted to serum-free growth media. After various periods of time (1-24 hours) , the medium was collected, concentrated and fractionated on a 12% polyacrylamide gel. The fractionated proteins were blotted to nitrocellulose and incubated with anti- bGH primary antibody followed by secondary incubation with 125 I-labelled protein A, from A ersham Inc. The bands were visualized by exposure on x-ray film (autoradiography) .) It would have been obvious for one of ordinary skill in the art before the effective filing date of the present disclosure to combine the disclosure of DIPASQUA with the teachings of ECKERT et al. to provide an electro spun bandage of FIG. 22 with nanoparticles that are radioactive to treat a disorder such as cancer and provide this in a bandage that includes two membranes for treating wounds using a fresh cellular product configuration with a permeable bottom membrane through which cellular product can diffuse and a separator between the two membranes for healing. See abstract. Eckert teaches “... 29. The bandage of claim 28, wherein the polyacrylonitrile nanofiber or polyacrylonitrile fiber has a diameter from about 150 nm to about 250 nm ” . (The potential growth hormone secreting cells were screened for secretion of growth hormone. The cells were grown until confluent in a 10 cm diameter dish (50 cm2) in normal growth media. The media was Dulbecco's Modified Eagle media in a 3 to 1 ratio with Ham's F12 and contained the supplements described above, and 80 ml fetal calf serum per liter. The cells were then shifted to serum-free growth media. After various periods of time (1-24 hours) , the medium was collected, concentrated and fractionated on a 12% polyacrylamide gel. The fractionated proteins were blotted to nitrocellulose and incubated with anti- bGH primary antibody followed by secondary incubation with 125 I-labelled protein A, from A ersham Inc. The bands were visualized by exposure on x-ray film (autoradiography) .) It would have been obvious for one of ordinary skill in the art before the effective filing date of the present disclosure to combine the disclosure of DIPASQUA with the teachings of ECKERT et al. to provide an electro spun bandage of FIG. 22 with nanoparticles that are radioactive to treat a disorder such as cancer and provide this in a bandage that includes two membranes for treating wounds using a fresh cellular product configuration with a permeable bottom membrane through which cellular product can diffuse and a separator between the two membranes for healing. See abstract. Dipasqua teaches “... 30. The bandage of claim 20, wherein the nanoparticles or particles have diameters of about 15 nm to about 250 nm. (see paragraph 150-156) Dipasqua discloses “.. 31. The bandage of claim 30, wherein the nanoparticles or particles have diameters of about 15 nm to about 200 nm. ” (see paragraph 51-52) Dipasqua discloses “. 32. The bandage of claim 20, wherein the activatable nuclide is holmium-165. (see paragraph 51) Claims 33-34 are rejected under 35 U.S.C. sec. 103 as being unpatentable as obvious in view of United States Patent Application Pub. No..: US2015/0202337A1 to DIPASQUA filed in 2014 and in view of International Patent Pub. No.: WO 1994/027633 A1 to Eckert et al. and in view of International Patent Pub. No.: WO2011/ 121394 A1 to Atteia . DIPASQUA discloses “... 33. A method of forming radiotherapeutic bandages comprising: a. preparing carrier nanoparticles or carrier particles comprising iron garnet and an activatable nuclide selected from the group consisting of yttrium-89, lanthanum-139, praseodymium-141, samarium-152, dysprosium-164, holmium- 165, rhenium-185, rhenium-187, and combinations thereof; (see paragraph 143 where there is a nanofibrous mat that includes an electro spun polymer material and including radiative and neutron activation materials in the covered area to damage dna in cancer cells) See also paragraphs 0005);[0046];(0051);[0067};[0068];[COSO};[0135];[0161]) “... b. drying and annealing the preparation; c. grinding the preparation; d. stirring and heating dimethylformamide (DMF) and polyacrylonitrile (PAN) and forming a concentration of 10% - 20% weight/volume PAN/DMF; e. mixing the preparation and DMF to form a suspension; f. sonicating the suspension in an ice bath; (see paragraph 73-86 and 96 and 144 and 70-79 ) . g. adding PAN/DMF to the suspension; h. mixing PAN/DMEF and the suspension to form a mixture; 1. adding the mixture to a carriage of an electrospinning instrument; (see paragraph 96-116) The primary reference is silent but Atteia teaches “.. j. electrospinning the mixture onto a paper substrate and forming a sheet; k. cutting the sheet into pieces; 1. enclosing and sealing the pieces with a polymer laminate; and m. forming a bandage by cutting or punching the enclosed and sealed laminated pieces ” (see pages 10-15 . ) It would have been obvious for one of ordinary skill in the art before the effective filing date of the present disclosure to combine the disclosure of DIPASQUA with the teachings of ATTEIA et al. to provide a wound care device that includes a film layer sheet 2 and a matrix layer 16. These can include a foam layer to allow fluid to pass and evaporate and to be produced by perforations that are disposed through the material. See abstract and pages 1-15. DIPASQUA discloses “... 34. The method of claim 33, wherein steps a. — f. are performed in a first space ” . (see paragraph 73-86 and 96-116) DIPASQUA discloses “... 35. The method of claim 34, wherein after step f., moving the PAN/DMEF and the carrier particle/DMF suspension to a first clean room and performing steps g. — k. (see paragraph 73-86 and 96-116) DIPASQUA discloses “... 36. The method of claim 35, wherein after step k., placing the pieces into a clean container, moving to a second clean room and performing step 1. (see paragraph 73-86 and 96-116) DIPASQUA discloses “... 37. The method of claim 35, wherein a clean down is performed after each of steps g. - k. (see paragraph 73-86 and 96-116) DIPASQUA discloses “... 38. The method of claim 36, wherein a clean down is performed after step 1. (see paragraph 73-86 and 96-116) DIPASQUA discloses “... 39. The method of claim 33, further comprises activating the bandage using neutron- activation. (see paragraph 21-23 and 133-135) Eckert teaches “...40. The method of claim 39, further comprises adding an adhesive to one side of the bandage. ”. (It is preferred that a layer of foam 21 be attached to the outer surface 22 of the top membrane 14 to provide rigidity to the bandage 10. The foam is of conventional materials, such as a closed cell polyurethane film-laminate, available from Semix Life Sciences Co., Frasier, Pennsylvania, preferably applied with an adhesive such as, for example, "Med 1118TT" from Avery Specialty Tape Co., Painsville , Ohio; or a tan spunlaced polyester film available under the trade name "5322P" from Avery Co. Preferably, the foam 21 is flesh colored for aesthetic purposes.) It would have been obvious for one of ordinary skill in the art before the effective filing date of the present disclosure to combine the disclosure of DIPASQUA with the teachings of ECKERT et al. to provide an electro spun bandage of FIG. 22 with nanoparticles that are radioactive to treat a disorder such as cancer and provide this in a bandage that includes two membranes for treating wounds using a fresh cellular product configuration with a permeable bottom membrane through which cellular product can diffuse and a separator between the two membranes for healing. See abstract. DIPASQUA teaches “... 41 . The method of claim 33, wherein stirring and heating the PAN/DMF concentration to make a 14.29% weight/volume PAN/DMF. (see paragraph 152) DIPASQUA discloses “.. 42. The method of claim 41, wherein mixing 1.21 g holmium iron garnet with 3.43 g DMF to form a suspension ” . (see paragraph 104 and 120-125 and 145) DIPASQUA discloses “. 43. The method of claim 42, wherein sonicating the suspension to form a homogeneous suspension. (see paragraph 79 and 104 and 120-125 and 145 )”. Any inquiry concerning this communication or earlier communications from the examiner should be directed to FILLIN "Examiner name" \* MERGEFORMAT JEAN PAUL CASS whose telephone number is FILLIN "Phone number" \* MERGEFORMAT (571)270-1934 . The examiner can normally be reached FILLIN "Work Schedule?" \* MERGEFORMAT Monday to Friday 7 am to 7 pm; Saturday 10 am to 12 noon . Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, FILLIN "SPE Name?" \* MERGEFORMAT Scott A. Browne can be reached at FILLIN "SPE Phone?" \* MERGEFORMAT 571-270-0151 . The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /JEAN PAUL CASS/ Primary Examiner, Art Unit 3666